Rationale: Angiotensin II (Ang II) has pleiotropic effects on vascular smooth muscle cells (VSMCs). It has been demonstrated to promote the proliferative phenotype of VSMCs in mouse ascending aorta, but the underlying mechanisms remain incompletely understood.
V ascular smooth muscle cells (VSMCs), the major constituent of blood vessels, play an essential role in the regulation of blood pressure, blood vessel tone, and blood flow distribution. Unlike the terminally differentiated skeletal or cardiac myocytes, VSMCs retain remarkable phenotypic plasticity in response to a wide variety of stimuli. Although the plasticity is indispensible for normal vascular development, dysregulated irreversible change in VSMC phenotype is associated with a number of cardiovascular diseases, including atherosclerosis, aneurysm, and hypertension.
1,2 The phenotypic modulation (or phenotypic switching) of VSMCs is a multifaceted process, and the underlying mechanisms remain incompletely defined. VSMCs express a repertoire of Ca 2+ -permeable ion channels, some of which have been implicated in phenotypic modulation of VSMCs. For instance, maintenance of the differentiated state of VSMCs requires voltage-gated Ca 2+ channels 3 ; Ca 2+ -permeable TRPC6 channels underlie pulmonary arterial hypertension by promoting proliferation of pulmonary VSMCs 4 ; the storeoperated Ca 2+ channel-Orai1-is involved in neointimal October 12, 2012
formation in the animal model of vascular injury. 5 All the evidence converges to highlight the importance of finely tuned Ca 2+ signaling in VSMC homeostasis. Transient receptor potential melastatin 7 (TRPM7), a member of TRP melastatin subfamily, is a Ca 2+ -permeable nonselective cation channel [6] [7] [8] whose expression has been detected in VSMCs. 9, 10 Through Ca 2+ signals, TRPM7 channels participate in many physiological and pathophysiological processes, including directed cell migration, 11 cell adhesion, 12 anoxic neuronal death, 13 and transdifferentiation of cardiac fibroblast. 14 Moreover, TRPM7 is essential for embryonic development, as evidenced by genetic ablation leading to embryonic lethality. 15, 16 However, the functional role of TRPM7-mediated Ca 2+ signaling in the phenotypic switching of VSMCs has not been explored.
VSMCs change their phenotype in response to various environmental cues, of which angiotensin II (Ang II) has been extensively studied. Ang II exerts multiple effects on vascular smooth muscle, including contraction of arteries under normal circumstances. Nevertheless, in certain forms of hypertension, persistent elevation of Ang II level gives rise to vascular remodeling, in which growth of VSMCs plays a pivotal role. 17, 18 The majority of the studies both in vitro and in vivo have demonstrated the hypertrophic effects of Ang II in rat thoracic aortic VSMCs, 19, 20 which are most widely used. Nonetheless, Owens et al recently reported an interesting observation that Ang II acts on mouse aorta in a region-specific manner; it promotes hyperplasia of the ascending aorta while inducing hypertrophy of the other aortic regions. 21 Inhibitor of differentiation 3 has been proposed to account for the differential effects, but it is unclear whether other molecules are also involved. In the present study, we attempted to explore whether the Ca 2+ -permeable ion channel-TRPM7-is involved in Ang II-mediated phenotypic modulation of ascending aortic VSMCs and whether TRPM7-mediated Ca 2+ signal is behind the phenotypic change.
Methods
For detailed experimental procedures, please see the Online Data Supplement.
RNA Extraction and Quantitative Real-Time PCR
Trizol reagents (Invitrogen) were used to extract RNA from cultured cells or tissues. Real-time PCR was carried out according to QuantiTect SYBR Green PCR Kit protocol (Qiagen) on the ABI fast real-time PCR system (Applied Biosystems). Gene expression was normalized versus GAPDH. 
Animal Model

Recording of TRPM7 Currents
Native TRPM7 currents were recorded as previously described.
14,22
For whole-cell recording, voltage ramps of 100-ms duration from −100 mV to +100 mV were applied at an interval of 2 seconds to cells held at 0 mV. 
Data Analysis
All data are expressed as mean±SEM. The n value denotes the number of independent experiments unless otherwise stated. Statistical analysis was determined by an unpaired 2-tailed Student t test or 1-way ANOVA followed by the Bonferroni multiple comparison post hoc test with a 95% confidence interval. Probability values of <0.05 were considered statistically significant.
Results
Ang II Increases TRPM7 Channel Expression In Vivo
Whereas TRPM7 protein has been detected in VSMCs, 9 its electrophysiological properties have not been characterized in VSMCs from the ascending aorta. In isolated ascending aortic VSMCs, a robust TRPM7-like current was readily recorded. The characteristic current-voltage relationship with small inward currents and strong outward currents resembles that of heterologously expressed TRPM7. 6, 8 The currents were inhibited by extracellular application of 100 μmol/L 2-APB, potentiated by removal of extracellular divalent ions, and inhibited by intracellular high Mg 2+ levels (Online Figure I) ; all of these properties are similar to those of the recombinant TRPM7. 23 Furthermore, the single-channel conductance of ≈33 pS was close to that of overexpressed TRPM7 channel. 23 Having characterized the native TRPM7 currents in VSMCs, we explored whether TRPM7 channel in aortic VSMCs is regulated by in vivo Ang II stimulation. The mouse model of Ang II infusion was established (Online Figure IIA) and TRPM7 currents were measured in freshly dispersed cells. Strikingly, whole-cell TRPM7 currents progressively increased after Ang II infusion, compared with the corresponding saline-infused controls ( Figure 1A and 1B Figure 1C ); this line of evidence is in line with Owens et al's observation that ascending aorta underwent hyperplasia rather than hypertrophy. 21 Generally, the increase in whole-cell currents can be attributed to elevated single-channel activity, increased protein abundance, and/or altered channel regulation. Single-channel measurement revealed that the single-channel properties, including open probability and slope conductance, were indistinguishable in VSMCs from control or Ang II-infused mice ( Figure 1D , 1E, and 1F). Of note, the Mg 2+ sensitivity of TRPM7 channel from both groups, revealed by the dose-response curves for Mg 2+ -mediated TRPM7 inhibition, was similar ( Figure 1G) . Collectively, the increase in macroscopic TRPM7 currents may be caused solely by elevated protein expression. The inference was substantiated by western blot analysis of TRPM7 protein ( Figure 1H and Online Figure IID) . Given the relative effects of Ang II on different aortic regions, 21 we also measured TRPM7 currents in VSMCs harvested from thoracic aorta at week 4 of Ang II infusion and found that TRPM7 currents were increased as well but to a lesser extent (Online Figure IIB) . Besides, VSMC capacitance in the Ang II group was elevated significantly, indicating a hypertrophy of thoracic aortic VSMCs (saline, 11.3±0.32pF; Ang II, 14.9±0.21pF; P<0.05; Online Figure IIC ).
Upregulation of TRPM7 by Ang II Type 1 Receptor-Elicited Extracellular Signal-Regulated Kinase Signaling
To understand how Ang II enhances TRPM7 protein expression, a set of in vitro experiments was performed. As displayed in Figure 2A , Ang II increased TRPM7 expression in a dose-dependent manner. Ang II treatment also led to a ≈2.3-fold rise in TRPM7 currents ( Figure 2B and 2C) . These results are in line with the in vivo findings. Ang II exerts its biological effects by binding to its cognate receptors, including Ang II type 1 receptor (AT1) and AT2. It was found that the AT1 blocker (losartan) effectively suppressed, whereas AT2 blocker (PD123319) slightly increased, TRPM7 transcripts (P<0.05, Figure 2D ). These results suggest that Ang II increased TRPM7 expression exclusively through AT1 receptor and that AT2 receptor signaling may act to attenuate AT1 signaling. AT1-elicited activation of mitogen-activated protein kinase (MAPK) pathway has been demonstrated to regulate the expression of a wide range of genes. To test the possibility of Ang II-elicited MAPK signaling also controlling TRPM7 expression, U0126, SB203580, and SP600125 were used to block MAPK extracellular signal-regulated kinase (ERK) kinase1/2 (MEK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK), respectively. The results showed that only U0126 offset Ang II-induced rise in TRPM7 mRNA levels ( Figure 2E ). The data obtained with the pharmacological blockers were strengthened by the application of specific small interfering RNA (siRNA) against AT1 and Figure 2F ). Taken together, TRPM7 expression was increased as a result of AT1-mediated ERK1/2 signaling. To find out whether the in vitro findings also hold true in vivo, we treated Ang II-infused mice with losartan or RDEA119-a potent and specific MEK1/2 inhibitor. 24, 25 As Figure 2G shows, both losartan and RDEA119 were able to normalize TRPM7 currents in ascending aortic VSMCs.
Ang II Infusion Changes the Cellular Phenotype of Ascending Aorta
Decreased expression of VSMC differentiation marker genes and increased proliferation rate are 2 cardinal features of VSMC phenotypic switching, 1,26 a transition from a contractile phenotype to a proliferative phenotype. Analysis of the phenotypic markers of differentiated VSMCs (SM-α-actin, SM-MHC, SM-22α) 1 and proliferation indicator (Ki-67) revealed phenotypic switching of ascending aorta during Ang II infusion, as indicated by downregulated VSMC differentiation markers and upregulated Ki-67 ( Figure 3A and Online Figure IIIA and B). The current paradigm holds that VSMC differentiation gene expression is controlled transcriptionally by interaction of the transcription factor-serum response factor (SRF)-with various transcriptional cofactors, such as ETS-like transcription factor 1 (Elk-1) and myocardin (Myocdn). [27] [28] [29] Myocardin, a transcriptional coactivator, is the master regulator of VSMC gene expression. 30 We assayed the expression levels of these transcriptional regulators in ascending aorta at 4 weeks of Ang II infusion and found that Ang II infusion did not change the expression of Myocdn, SRF, and total Elk-1 protein, whereas the phosphorylated Elk-1 was increased ( Figure 3B and Online Figure IIIC ). As shown in Figure  3C , 3D, and 3E, the mRNA levels of neither Myocdn, SRF, nor Elk-1 were altered, suggesting no change in expression at the transcription level. Collectively, the increase in phosphorylated Elk-1 may account for reduced expression of VSMC differentiation genes during Ang II administration, consistent with the role of phosphor-Elk-1 in PDGF-mediated suppression of VSMC gene expression. 28 In light of the Ca 2+ permeability of TRPM7 channel, Ca 2+ influx was measured in isolated ascending aortic cells as described previously in cardiac fibroblast.
14 Technically, the cells were perfused with nominally divalent-free solution (DVF, Ca -containing solution; 20 mmol/L Ca 2+ was used to increase Ca 2+ signal/noise ratio. As Figure 3F shows, Ca 2+ entry in cells from Ang II-infused mice was substantially increased by ≈1.9-fold (peak value, P<0.01), compared with the controls. The observed Ca 2+ signals in freshly dissociated VSMCs are most probably mediated by TRPM7 because the Ca 2+ signals evoked by the above-described method were almost abrogated by TRPM7 knockdown in cultured ascending aortic VSMCs (Online Figure IIIE) . -sensitive proline-rich tyrosine kinase, 31 and its downstream kinases MEK1/2-ERK1/2, which has been linked to PDGF-mediated inhibition of VSMC gene expression. 28 It was found that the activity of Pyk2-MEK1/2-ERK1/2 was significantly increased by Ang II infusion ( Figure 3G and Online Figure IIID ).
TRPM7 Switches Cell Phenotype and Promotes Cell Proliferation In Vitro
After the in vivo observation that TRPM7 channel function was inversely correlated with the expression of VSMC differentiation markers, we attempted to establish a causal relationship between them by means of TRPM7 silencing with siRNA. A pair of TRPM7-targeting siRNA sequences (siR-NA1 and siRNA2) was evaluated and siRNA1 was used in the study due to a slightly better efficiency (Online Figure IVA  through C) . Furthermore, Ang II was demonstrated to be able to modulate the phenotype of ascending aorta, as indicated by reduced VSMC gene expression (SM-α-actin, SM-MHC, SM-22α, calponin). It did not affect the expression levels of the transcriptional regulators of VSMC differentiation (Myocdn, SRF, Elk-1) and Pyk2. TRPM7 was shown to be required for Ang II-triggered phenotypic modulation of ascending aortic VSMCs because deficiency of TRPM7 largely restored VSMC gene expression in Ang II-treated cells ( Figure 4A ). Meanwhile, cell phenotype analysis in thoracic aortic VSMCs showed that Ang II increased and TRPM7 knockdown nearly normalized VSMC gene expression (SM-α-actin, SM-MHC, and SM-22α; Online Figure IVD) . Despite the differential effects of Ang II on VSMC genes, suppression of TRPM7 normalized VSMC gene expression in both ascending and thoracic aortic VSMCs.
We subsequently evaluated if TRPM7 promotes Ang IIeninduced proliferation of aortic VSMCs. In cultured VSMCs harvested from ascending aorta, Ang II induced significant VSMC proliferation, which was dramatically inhibited on TRPM7 knockdown, as indicated by cell count and BrdU incorporation ( Figure 4B and 4C) . Also, Ang II treatment facilitated cell cycle transition from quiescent G 0 /G 1 to synthetic S phase ( Figure 4D ). However, cell cycle distribution of thoracic aortic VSMCs did not change in the presence of Ang II, and TRPM7 suppression exerted no effects (Online Figure IVE) .
Pyk2 Activation by TRPM7-Mediated Ca 2+ Influx Controls VSMC Gene Expression
In vivo experiments showed that the signaling pathway Pyk2-ERK1/2 and its downstream target Elk-1 were activated during Ang II infusion (Figure 3 ), but whether TRPM7 is required for pathway activation must be validated. We treated cultured ascending aortic VSMCs with negative or specific TRPM7 siRNA and then examined the pathway after Ang II treatment. As in Figure 5A , Ang II treatment led to activation of Pyk2 and ERK1/2, which in turn phosphorylates Elk-1; no change in Myocdn and SRF protein levels was observed. Intriguingly, TRPM7 knockdown considerably inhibited the activation of the pathway Pyk2-ERK1/2-Elk-1, suggesting a causal link between TRPM7 and Ang II-mediated activation of Pyk2 ( Figure 5A and Online Figure VA) . Nonetheless, 2 questions arise: (1) does acute application of Ang II influence TRPM7 channel activity, and (2) does TRPM7 opening activate Pyk2? Using a relatively physiological recording condition (see Figure 5B and 5C), we found that TRPM7 currents were significantly potentiated by ≈30% in response to Ang II. Besides, knockdown of TRPM7 with siRNA in cultured ascending aortic VSMCs led to significantly reduced Ca 2+ entry in response to Ang II, indicating the contribution of TRPM7 to Ang II-induced Ca 2+ influx (Online Figure VB) . TRPM7 silencing abrogated Ang II-induced amplification of TRPM7 currents in cultured ascending aortic VSMCs (Online Figure  VC and D) . The evidence collectively suggests that Ang IImediated TRPM7 opening and resultant Ca 2+ entry contributed to Pyk2 activation. To examine if TRPM7-mediated Ca October 12, 2012 solution was applied, as in Ca 2+ imaging experiment. The results showed that Pyk2 was activated when Ca 2+ was re-added to DVF-treated cells and that Pyk2 activation was inhibited in cells with reduced TRPM7 (Figure 5D and Online Figure VE ). In conclusion, TRPM7 opening induced Ca 2+ influx, and Pyk2 activation ensued.
Next, we attempted to investigate whether Ang II alters the transcriptional program that controls VSMC gene expression and whether TRPM7-Pyk2-ERK1/2-Elk-1 signaling is involved in Ang II-elicited suppression of VSMC gene transcription. As detected by coimmunoprecipitation, Ang II stimulation enhanced the association of Elk-1 with SRF, accompanied by a decline in Myocdn-SRF association ( Figure 5E ). In addition, as revealed by ChIP assay (Figure 5F and 5G), association of Elk-1 with SRF-binding sites (CArG box sequence) in the promoter of SM-22 was increased in response to Ang II, which was accompanied by a decreased occupancy by Myocdn of the same sites. These data suggest a signal-dependent competitive exchange of Elk-1 for Myocdn on SRF in the promoter region of SMC gene in the presence of Ang II in ascending aortic VSMCs. Notably, these effects exerted by Ang II on VSMC gene transcription was reversed by TRPM7 knockdown, and ectopic expression of constitutively active c-Src largely counteracted the effects of TRPM7 suppression ( Figure 5E through 5G). c-Src kinase is the direct downstream target of Pyk2 31 and was used in the present study due to the lack of constitutively active Pyk2 mutant. 32 To firmly establish that TRPM7-Pyk2-ERK1/2-Elk-1 pathway activated by Ang II represses the differentiation gene expression of ascending aortic VSMCs, specific siRNA sequence against TRPM7, Pyk2, ERK1/2, and Elk-1 was individually applied to the cultured Ang II-treated VSMCs, and SM-22 mRNA levels were determined. As shown in Figure 5H , SM-22 mRNA levels were nearly normalized by siRNA treatment against the pathway. Moreover, reconstitution of the whole pathway by introducing constitutively active mutants of c-Src, ERK1, Elk-1 to TRPM7-silenced VSMCs abrogated the effects of TRPM7 suppression on SM-22 expression, suggesting that ERK1/Elk-1 is downstream of TRPM7 and regulates the marker gene expression of ascending aortic VSMCs ( Figure 5I ). Transfection of wild-type c-Src, ERK1, and Elk-1 did not change SM-22 expression (Online Figure VF) . Together, TRPM7-Pyk2-ERK1/2-Elk-1 signaling plays a key role in transcriptionally controlling the expression of VSMC marker gene.
Discussion
The present study investigated the phenotypic modulation of VSMCs by TRPM7, a member of TRPM channel family, which is constitutively active and brings Ca 2+ into cells under physiological conditions. Our data demonstrated that Ang II upregulated TRPM7 channels in ascending aortic VSMCs and that TRPM7-mediated Ca 2+ signals activated Pyk2-ERK1/2-Elk-1 signaling pathway and thus suppressed VSMC gene expression.
Many studies have demonstrated the hypertrophic effects of Ang II on the commonly cultured rat 48 hours (B, C, and D) . A, mRNA levels of the indicated genes, in cells treated with none (control, Ctrl), Ang II alone (Ang II), Ang II plus negative siRNA (Ang II+Neg), and Ang II plus TRPM7-specific siRNA (Ang II+siRNA). The mRNA levels were normalized versus control (n=6). B through D, Cell proliferation as assayed by BrdU incorporation (B), cell counting (C), and cell cycle distribution (D). Cultured VSMCs were subjected to corresponding treatments as indicated (n=6). thoracic aortic VSMCs, 19, 20 whereas a lesser number have revealed proliferation. 33 The discrepancy in growth response in in vitro experiments is thought to result from cell culture conditions, including cell type, cell passage, cell confluence, and cytokine milieu. 18, 33, 34 Of interest, Owens et al defined the region-specific effects of Ang II infusion on mouse aortic media. Chronic administration of Ang II promotes uniform medial thickening of the whole aorta, but the underlying cause differs in a region-specific fashion. VSMCs hyperplasia occurs in the ascending aorta, whereas hypertrophy of VSMCs is evident in all other aortic parts (thoracic, abdominal, suprarenal, infrarenal). In vitro experiments reveal that Ang potently stimulates cell proliferation in ascending aortaderived VSMCs but has no effects on other aortic VSMCs of different origin. 21 Consistent with Owens et al's finding, our cell cycle assays showed that Ang II significantly facilitated cell cycle progression of ascending aortic VSMCs from G 0 / G 1 to S phase but barely affected that of thoracic VSMCs. Suppression of TRPM7 considerably inhibited both cell proliferation rate and cell cycle progression, indicating the proproliferative role of TRPM7 in ascending aorta VSMCs. Indeed, TRPM7 channel has been implicated in cell proliferation in many other cell types, including chicken DT-40 B cells, 6 tumor cells, 35 and cardiac fibroblasts. 14 Strikingly, a novel difference between ascending and nonascending aortic VSMCs was uncovered in our study; VSMC gene expression was reduced by Ang II in ascending aortic VSMCs but an enhancement was observed in the cells from thoracic aorta. Despite the opposite reactions to Ang II, TRPM7 suppression normalized VSMC gene expression in both cells. This indicates that block of TRPM7 in vivo would be beneficial to all aortic regions in the setting of chronic Ang II stimulation. Presently, the pathological significance of VSMC proliferation in the ascending aorta remains unknown, but Ang II-related diseases such as heart failure could be aggravated by expanded ascending aorta because of increased afterload. The diverse responses to Ang II may be attributable to the heterogeneity in embryonic origin of aortic VSMC 36, 37 ; VSMCs in ascending aorta are derived from neural crest, whereas thoracic aortic VSMCs are from somite lineage. 36, 38 Ang II has been known to regulate the expression and/or activity of many ion channels. For example, it downregulates Ca 2+ -activated Cl − channel TMEM16A in cerebral VSMCs 39 and large conductance Ca 2+ -activated K + channels during hypertension. 40 In the present study, we identified TRPM7 as a target of Ang II. Based on our findings, we propose that Ang II amplifies TRPM7-mediated Ca 2+ signals and the downstream pathway Pyk2-ERK1/2-Elk-1 and hence promotes the proliferative phenotype of ascending aorta. Nevertheless, it should be pointed out that Ang II might also act on other Ca 2+ -permeable channels (possibly TRPC channel and Orai channel), which have not been explored in ascending aortic VSMCs, to fulfill its proproliferative role. In the context of Ang II-triggered proliferation of ascending aorta, TRPM7 may be a unique ion channel target of Ang II, since (1) it is a constitutively active Ca 2+ -permeable channel abundantly expressed in ascending aortic VSMCs, and (2) its proliferation-promoting actions have been well documented in many cell types. Our results revealed that TRPM7 expression was elevated due to AT1 receptor-mediated ERK1/2 activation. Interestingly, in vivo administration of either AT1 receptor blocker or ERK1/2 blocker abolished Ang II-induced increase in TRPM7 function. Together with our finding that TRPM7 in ascending aortic VSMCs is required for ERK1/2 signaling, these data suggest that AT1 receptor and TRPM7 channels probably form a positive feedback loop through ERK1/2 signaling; AT1-mediated activation of ERK1/2 increases TRPM7 expression, which in turn aggravates ERK1/2 signaling through Pyk2 activation. This feedback loop may have pathological implications, but it must be verified in vivo. Additionally, we found that TRPM7 protein in ascending aortic VSMCs was elevated during Ang II infusion to a much larger extent, compared with thoracic aortic VSMCs. Despite the consistency in TRPM7 upregulation, the difference in fold increase may play a role in determining the relative effects of Ang II in specific aortic parts, because the strength and duration of Ca 2+ signal is known to preferentially activate signaling pathways. 41, 42 Although it is generally believed that Ang II is a contractile agonist, the evidence from Owens et al's and ours strongly indicates that Ang II acts on ascending aortic VSMCs as a mitogenic agonist, which, exemplified by platelet-derived growth factor BB (PDGF), substantially suppresses VSMC differentiation. 43 It has been defined that PDGF suppresses VSMC gene expression by activating ERK1/2 and consequently phosphorylating the ternary complex factor-Elk-1.
28 Phosphorylated Elk-1 competes for SRF with myocardin, which is a master regulator of VSMC differentiation gene expression. 28, 30 Based on the similarity between Ang II and PDGF with regard to the effects on ascending aortic VSMCs, it is plausible to hypothesize that these 2 vasoactive factors may use similar mechanisms to regulate VSMC gene expression. The hypothesis was corroborated in our study. Ang II stimulation gave rise to activation of ERK1/2 and phosphorylation of Elk-1. As a result, myocardin was displaced from SRF. Knockdown of TRPM7 considerably ameliorated ERK1/2 activation as well as Elk-1 phosphorylation. Remarkably, the dynamic competition for SRF binding between phosphorElk-1 and myocardin was regulated by TRPM7 channel, as revealed by TRPM7 knockdown experiment. In delineating how TRPM7 contributes to activation of ERK1/2-Elk-1 pathway, we focused on Pyk2 31 because it serves as an upstream kinase of ERK1/2 signaling and importantly is sensitive to cytosolic Ca 2+ . The involvement of Pyk2 in Ang II signaling is well documented in rat thoracic aortic VSMCs, 44, 45 but the Ca 2+ source for Pyk2 activation remains incompletely defined. In the present study, we demonstrated that TRPM7 opening provided Ca 2+ to activate Pyk2 in ascending aortic VSMCs. More importantly, activation of Pyk2 by TRPM7-mediated Ca 2+ signals potentiated ERK1/2 signaling and thus resulted in suppression of VSMC gene expression. Pyk2 has been shown to relay TRPM2 channel-mediated Ca 2+ signals to NF-κB activation in monocytes 46 and participate in TRPC channel-mediated neuronal survival. 47 Our description of TRPM7 activating Pyk2 in VSMCs is the first, to the best of our knowledge.
The phenotype of VSMCs is modulated by many environmental cues, and, in the present study, Ang II was demonstrated to be highly proproliferative in ascending aortic VSMCs. Mechanistically, Ang II upregulates the expression of the Ca 2+ -permeable TRPM7 channels and augments TRPM7-mediated Ca 2+ signals, which in turn activate Pyk2-ERK1/2-Elk-1 and reprogram VSMCs to suppress differentiation and promote proliferation. Elk-1 phosphorylation due to TRPM7-Pyk2-ERK1/2 is capable of coordinating the 2 aspects of VSMC phenotypic modulation. On one hand, phospho-Elk-1 displaces myocardin from SRF on the promoters of VSMC differentiation genes and hence suppresses VSMC gene expression. On the other hand, it binds to SRF on the promoter of proto-oncogenic genes, such as c-fos, to increase the proliferation rate. Based on our data, we propose that the signal transduction by TRPM7-Pyk2-ERK1/2-Elk-1 may represent an important mechanistic basis for Ang II-induced phenotypic switching of ascending aortic VSMCs. Although our in vivo data clearly showed that Pyk2-ERK1/2-Elk-1 pathway as well as TRPM7 function was enhanced by Ang II infusion, the decisive link between TRPM7 and the pathway activation awaits validation in vivo with the use of VSMC-specific TRPM7 deletion. Furthermore, it is still unclear whether TRPM7 channel is involved in VSMC phenotypic change induced by other agonists, such as PDGF and TGF-β. 
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